EXTENDED-SPECTRUM BETA-LACTAMASE-PRODUCING ENTEROBACTERIACEAE IN CRITICALLY ILL PATIENTS: IMPACT OF CARRIAGE AND INFECTION ON CARBAPENEM CONSUMPTION, DURATION OF ICU STAY, AND MORTALITY by F Barbier et al.
ORAL PRESENTATION Open Access
Extended-spectrum beta-lactamase-producing
Enterobacteriaceae in critically ill patients: impact
of carriage and infection on carbapenem
consumption, duration of icu stay, and mortality
F Barbier1*, C Pommier2, M Garrouste-Orgeas3, C Schwebel4, S Ruckly5, AS Dumenil6, V Lemiale7, B Mourvillier8,
C Clec’h9, M Darmon10, V Laurent11, G Marcotte12, B Souweine13, JR Zahar14, JF Timsit8,
for the OUTCOMEREA Study Group
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Introduction
The spread of extended-spectrum beta-lactamase-produ-
cing Enterobacteriaceae (ESBL-E) is a major issue in
ICU patients. Whether ESBL-E carriage and infection
impact the outcome and the use of carbapenems in this
population remains scarcely evaluated.
Objectives
We investigated the effects of ESBL-E carriage and
infection on carbapenem consumption, ICU length of
stay (LOS), and adjusted probability of death at day-28
(D28) in a multicenter cohort of critically ill patients.
Methods
Adult patients admitted between January 1996 and
December 2013 in 17 French ICUs contributing to the
OUTCOMEREA prospective database were included.
Screening for ESBL-E carriage was performed at ICU
admission and weekly thereafter. A cause-specific hazard
model was built to assess the impact of carriage with
and without ICU-acquired infection due to ESBL-E on
the likelihood of death or ICU discharge at D28.
Results
Among the 16,734 included patients, 594 (3.5%) were
colonized with ESBL-E during their ICU stay (imported
carriage, 52.2%). A total of 118 ESBL-E infections
occurred in 98 carriers (16.4%). Both ESBL-E infections
and ESBL-E carriage without infection increased the use
of carbapenems during the ICU stay when compared to
non-carriage (627, 241 and 69 treatment days for 1,000
patient-days, respectively, p < 0.001 for all comparisons).
The ICU LOS was longer in carriers than in non-carriers
(median [IQR], 13 [6-26] vs 5 [3-9] days, p < 0.01) but
similar in carriers with and without ESBL-E infection
(13 [6-29] vs 13 [6-26] days, p = 0.52). Crude mortality
rates at D28 were higher in carriers than in non-carriers
(19.7% vs 15.6%, p < 0.01), and further differed when com-
paring carriers with ESBL-E infections and uninfected car-
riers (30.6% vs 17.5%, p < 0.01). After adjustment on
baseline (chronic diseases, type of admission, and SAPS II
and organ failures at ICU admission) and time-dependent
(SOFA score at the time of ESBL-E acquisition, and end-
of-life decisions) variables, ESBL-E infections increased the
risk of death at D28 [adjusted cause-specific hazard ratio
(aCSHR) 1.825, 95% confidence interval (95%CI) 1.235-
2.699, p = 0.003] and the ICU LOS (aCSHR 0.563, 95%CI
0.432-0.733, p < 0.001). ESBL-E carriage without infection
prolonged the ICU stay (aCSHR 0.623, 95%CI 0.553-0.702,
p < 0.001), but had no effect on D28 mortality (aCSHR
0.906, 95%CI 0.722-1.136, p = 0.4). When analyzed sepa-
rately, the effects of carriage and infection did not differ
between ESBL-producing Escherichia coli (48.7% of
carriage isolates) and other ESBL-E.
Conclusions
In this large cohort of critically ill patients, ESBL-E infec-
tions increased carbapenem consumption, ICU LOS, and1La Source Hospital - CHR Orléans, Medical ICU, Orléans, France
Full list of author information is available at the end of the article
Barbier et al. Intensive Care Medicine Experimental 2015, 3(Suppl 1):A1
http://www.icm-experimental.com/content/3/S1/A1
© 2015 Barbier et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
D28 mortality. Less than one fifth of carriers developed an
ESBL-E infection; however, even ESBL-E carriage without
infection increased carbapenem exposure and delayed
discharge, thereby amplifying both the selective pressure
and the colonization pressure in the ICU.
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